Cargando…

Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study

BACKGROUND: Cefazolin is a commonly used antibiotic for the treatment of mild to severe infections. Despite the use of higher dose of cefazolin (3 g/dose) for surgical prophylaxis in patients with obesity, there is currently a paucity of data identifying the optimal dose to treat infections in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, HaYoung, Mohayya, Sana, Hong, Thomas, Modi, Mansi, Yang, Jaehee, Abdul Azim, Ahmed, Bhatt, Pinki J, Brunetti, Luigi, Narayanan, Navaneeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946698/
https://www.ncbi.nlm.nih.gov/pubmed/35350175
http://dx.doi.org/10.1093/ofid/ofac105
_version_ 1784674255290499072
author Ryu, HaYoung
Mohayya, Sana
Hong, Thomas
Modi, Mansi
Yang, Jaehee
Abdul Azim, Ahmed
Bhatt, Pinki J
Brunetti, Luigi
Narayanan, Navaneeth
author_facet Ryu, HaYoung
Mohayya, Sana
Hong, Thomas
Modi, Mansi
Yang, Jaehee
Abdul Azim, Ahmed
Bhatt, Pinki J
Brunetti, Luigi
Narayanan, Navaneeth
author_sort Ryu, HaYoung
collection PubMed
description BACKGROUND: Cefazolin is a commonly used antibiotic for the treatment of mild to severe infections. Despite the use of higher dose of cefazolin (3 g/dose) for surgical prophylaxis in patients with obesity, there is currently a paucity of data identifying the optimal dose to treat infections in this specific patient population. METHODS: This was a multicenter, retrospective cohort study of patients who received cefazolin at weight-based (up to 9 g/day) or standard doses (up to 6 g/day) for the treatment of bacteremia or skin and soft tissue infection (SSTI). Study groups were stratified by body weight and cefazolin dose received. Primary outcome was the composite of treatment-emergent adverse events (TEAEs) and secondary outcome was treatment failure rate. RESULTS: A total of 208 patients were included for study analysis. Fifty-nine patients had body weight >120 kg. Of these, 33 received high-dose cefazolin while 26 received standard doses. The remaining 149 patients had body weight of ≤120 kg and received standard doses. The occurrence of TEAEs did not differ across the 3 groups. The study also did not find any difference between the rate of treatment failure between groups. CONCLUSIONS: High-dose cefazolin (9 g/day) for the treatment of bacteremia or SSTIs in patients with high body weight was safe and well tolerated. Larger studies are needed to further explore the benefit of high-dose cefazolin in improving clinical outcomes.
format Online
Article
Text
id pubmed-8946698
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89466982022-03-28 Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study Ryu, HaYoung Mohayya, Sana Hong, Thomas Modi, Mansi Yang, Jaehee Abdul Azim, Ahmed Bhatt, Pinki J Brunetti, Luigi Narayanan, Navaneeth Open Forum Infect Dis Major Article BACKGROUND: Cefazolin is a commonly used antibiotic for the treatment of mild to severe infections. Despite the use of higher dose of cefazolin (3 g/dose) for surgical prophylaxis in patients with obesity, there is currently a paucity of data identifying the optimal dose to treat infections in this specific patient population. METHODS: This was a multicenter, retrospective cohort study of patients who received cefazolin at weight-based (up to 9 g/day) or standard doses (up to 6 g/day) for the treatment of bacteremia or skin and soft tissue infection (SSTI). Study groups were stratified by body weight and cefazolin dose received. Primary outcome was the composite of treatment-emergent adverse events (TEAEs) and secondary outcome was treatment failure rate. RESULTS: A total of 208 patients were included for study analysis. Fifty-nine patients had body weight >120 kg. Of these, 33 received high-dose cefazolin while 26 received standard doses. The remaining 149 patients had body weight of ≤120 kg and received standard doses. The occurrence of TEAEs did not differ across the 3 groups. The study also did not find any difference between the rate of treatment failure between groups. CONCLUSIONS: High-dose cefazolin (9 g/day) for the treatment of bacteremia or SSTIs in patients with high body weight was safe and well tolerated. Larger studies are needed to further explore the benefit of high-dose cefazolin in improving clinical outcomes. Oxford University Press 2022-02-28 /pmc/articles/PMC8946698/ /pubmed/35350175 http://dx.doi.org/10.1093/ofid/ofac105 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Ryu, HaYoung
Mohayya, Sana
Hong, Thomas
Modi, Mansi
Yang, Jaehee
Abdul Azim, Ahmed
Bhatt, Pinki J
Brunetti, Luigi
Narayanan, Navaneeth
Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study
title Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study
title_full Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study
title_fullStr Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study
title_full_unstemmed Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study
title_short Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study
title_sort safety and effectiveness of high-dose cefazolin in patients with high body weight: a retrospective cohort study
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946698/
https://www.ncbi.nlm.nih.gov/pubmed/35350175
http://dx.doi.org/10.1093/ofid/ofac105
work_keys_str_mv AT ryuhayoung safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy
AT mohayyasana safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy
AT hongthomas safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy
AT modimansi safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy
AT yangjaehee safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy
AT abdulazimahmed safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy
AT bhattpinkij safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy
AT brunettiluigi safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy
AT narayanannavaneeth safetyandeffectivenessofhighdosecefazolininpatientswithhighbodyweightaretrospectivecohortstudy